Jazz Pharmaceuticals (JAZZ) Operating Expenses (2010 - 2026)

Jazz Pharmaceuticals' Operating Expenses history runs 17 years deep, the most recent figure standing at $732.3 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 23.21% year-over-year to $732.3 million; the TTM figure through Mar 2026 stood at $4.5 billion (up 28.99% YoY), while the FY2025 annual figure was $4.7 billion, up 40.14% from the prior year.
• Operating Expenses for Q1 2026 stood at $732.3 million, down from $943.4 million in the prior quarter.
• The five-year high for Operating Expenses was $1.7 billion in Q2 2025, with the low at $726.2 million in Q1 2022.
• The 5-year median for Operating Expenses is $847.3 million (2022), against an average of $927.2 million.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses decreased 28.01% in 2023, then surged 110.11% in 2025.
• Jazz Pharmaceuticals' Operating Expenses stood at $1.2 billion in 2022, then fell by 28.01% to $889.4 million in 2023, then climbed by 0.9% to $897.4 million in 2024, then advanced by 5.12% to $943.4 million in 2025, then decreased by 22.38% to $732.3 million in 2026.
• Business Quant data shows JAZZ's Operating Expenses at $732.3 million in Q1 2026, $943.4 million in Q4 2025, and $1.1 billion in Q3 2025.